Long‐Term Medication‐Induced Weight Change Across Common Antiseizure Medications: A Target Trial Emulation Study
Obesity · 2025-12 · 33 (12) · 2355-2364
DOI: 10.1002/oby.24362 ↗At a glance
Journal article in Obesity, published online on 2025-10-05. Written by Han Yu and 13 co-authors. Institution: Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. Major MEDLINE topics: Anticonvulsants, Weight Gain, Weight Loss, Epilepsy. Cited 5 times so far (Crossref); 45 references. Funded by: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (original language)
Objective
To estimate long‐term weight change after initiation and adherence to commonly used antiseizure medications (ASMs) and examine differences in weight change across ASMs compared to topiramate.
Methods
We included 52,309 adult patients who initiated ASMs, applied a target trial emulation approach to control time‐varying confounding and selection bias, and examined the long‐term comparative effects on weight change after initiating and adhering to different ASMs at 6 and 12 months post initiation.
Results
The most commonly initiated ASM was topiramate (41.2%). In comparison to topiramate, we estimated higher 6‐month weight change under initiation and adherence to levetiracetam 0.94 kg (95% CI 0.20, 1.64), lamotrigine 1.44 kg (0.74, 1.99), valproate 2.42 kg (1.71, 2.88), carbamazepine 1.32 kg (0.46, 2.16), and oxcarbazepine 1.74 kg (0.85, 2.71), with similar results at 12 months and in sensitivity and subgroup analyses. These results were driven mostly by weight loss with use of topiramate rather than weight gain with use of other ASMs. Results were similar though attenuated when accounting for medication initiation only.
Conclusions
Topiramate was associated with weight loss at 6 and 12 months under either initiation and subsequent adherence or initiation‐only effects; other medications were associated with higher weight change. These results provided important information to help with decision‐making regarding ASM initiation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado, USA.
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Clinical and Health Psychology, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, USA.
- Division of Cardiology, Duke University Department of Medicine, Durham, North Carolina, USA.
ORCID profiles: Han Yu, Joshua Petimar, William J Heerman, David M Janicke, Kristina H Lewis
Funding
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Cite
APA
Yu, H., Young, J. G., Petimar, J., Rifas-Shiman, S. L., Daley, M. F., Heerman, W. J., Janicke, D. M., Jones, W. S., Kawahara, T., Lewis, K. H., Lin, P. D., Toh, S., Weisholtz, D. S., & Block, J. P. (2025). Long‐Term Medication‐Induced Weight Change Across Common Antiseizure Medications: A Target Trial Emulation Study. Obesity, 33(12), 2355-2364. https://doi.org/10.1002/oby.24362
Vancouver
Yu H, Young JG, Petimar J, Rifas-Shiman SL, Daley MF, Heerman WJ, et al. Long‐Term Medication‐Induced Weight Change Across Common Antiseizure Medications: A Target Trial Emulation Study. Obesity. 2025;33(12):2355-2364. doi:10.1002/oby.24362
BibTeX
@article{Yu2025,
author = {Yu, Han and Young, Jessica G and Petimar, Joshua and Rifas-Shiman, Sheryl L and Daley, Matthew F and Heerman, William J and Janicke, David M and Jones, W Schuyler and Kawahara, Takuya and Lewis, Kristina H and Lin, Pi-I D and Toh, Sengwee and Weisholtz, Daniel S and Block, Jason P},
title = {Long‐Term Medication‐Induced Weight Change Across Common Antiseizure Medications: A Target Trial Emulation Study},
journal = {Obesity},
year = {2025},
volume = {33},
number = {12},
pages = {2355--2364},
doi = {10.1002/oby.24362}
}
EUVIMED